Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mipsagargin in Recurrent or Progressive Glioblastoma
NCT02067156Phase 2Completed
- Sponsor
- Inspyr Therapeutics
- Start
- Feb 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of mipsagargin in glioblastoma (GBM), sponsored by Inspyr Therapeutics. Started Feb 2014; status: completed.
02
Drugs
mipsagargin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02067156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02067156.